{"id":344948,"date":"2025-08-24T14:26:21","date_gmt":"2025-08-24T14:26:21","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-ab-science-sa\/"},"modified":"2025-08-24T14:26:21","modified_gmt":"2025-08-24T14:26:21","slug":"how-to-buy-ab-science-sa","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/","title":{"rendered":"AB Science S.A. (AB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AB Science S.A. (AB) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334099,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-344948","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"AB Science S.A. (AB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AB Science S.A. (AB) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"AB Science S.A. (AB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AB Science S.A. (AB) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"AB Science S.A. (AB) hisselerini nas\u0131l alaca\u011f\u0131n\u0131z\u0131, mevcut fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyelini kapsayan kapsaml\u0131 yat\u0131r\u0131m analizimizle \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"AB Science S.A. (AB) hisselerini nas\u0131l alaca\u011f\u0131n\u0131z\u0131, mevcut fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyelini kapsayan kapsaml\u0131 yat\u0131r\u0131m analizimizle \u00f6\u011frenin."},"intro":"\u0130leri biyoteknoloji yeniliklerine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? AB Science S.A., klinik at\u0131l\u0131mlar\u0131n hasta ya\u015famlar\u0131n\u0131 ve yat\u0131r\u0131mc\u0131 portf\u00f6ylerini d\u00f6n\u00fc\u015ft\u00fcrebilece\u011fi heyecan verici ila\u00e7 geli\u015ftirme d\u00fcnyas\u0131n\u0131 temsil ediyor. Bu Frans\u0131z biyofarma \u015firketi, kanser ve inflamatuar hastal\u0131klar i\u00e7in kinaz inhibit\u00f6rlerinde uzmanla\u015fm\u0131\u015f olup, ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in hem \u00f6nemli riskler hem de ola\u011fan\u00fcst\u00fc potansiyel \u00f6d\u00fcller sunmaktad\u0131r.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0130leri biyoteknoloji yeniliklerine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? AB Science S.A., klinik at\u0131l\u0131mlar\u0131n hasta ya\u015famlar\u0131n\u0131 ve yat\u0131r\u0131mc\u0131 portf\u00f6ylerini d\u00f6n\u00fc\u015ft\u00fcrebilece\u011fi heyecan verici ila\u00e7 geli\u015ftirme d\u00fcnyas\u0131n\u0131 temsil ediyor. Bu Frans\u0131z biyofarma \u015firketi, kanser ve inflamatuar hastal\u0131klar i\u00e7in kinaz inhibit\u00f6rlerinde uzmanla\u015fm\u0131\u015f olup, ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in hem \u00f6nemli riskler hem de ola\u011fan\u00fcst\u00fc potansiyel \u00f6d\u00fcller sunmaktad\u0131r."},"body_html":"<h2>\ud83d\udcc8 AB Science Hissesi: Mevcut Fiyat ve Piyasa Konumu<\/h2> <p>24 A\u011fustos 2025 itibar\u0131yla, AB Science S.A. (AB.PA) Euronext Paris'te <strong>1,29\u20ac<\/strong> fiyatla i\u015flem g\u00f6rmektedir. \u015eirketin piyasa de\u011feri yakla\u015f\u0131k 79,24 milyon euro olup, mikro-cap kategorisinde yer almakta\u2014y\u00fcksek b\u00fcy\u00fcme f\u0131rsatlar\u0131 ve buna ba\u011fl\u0131 risk seviyeleri arayan yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p> <p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131: 30 Eyl\u00fcl 2025<\/strong>, \u015firketin bir sonraki kazan\u00e7 a\u00e7\u0131klamas\u0131n\u0131 i\u015faret etmektedir. Tarihsel veriler, bu t\u00fcr olaylar\u0131n genellikle \u00f6nemli fiyat hareketlerine yol a\u00e7t\u0131\u011f\u0131n\u0131 g\u00f6stermektedir. \u00d6nceki kazan\u00e7 raporu 9 May\u0131s 2025'te yay\u0131mlanm\u0131\u015f olup, olumlu klinik deneme haberlerinin \u00f6nemli kazan\u00e7lar\u0131 tetikledi\u011fi g\u00f6r\u00fclm\u00fc\u015ft\u00fcr.<\/p> <h3>Son Fiyat Performans\u0131 Analizi<\/h3> <table> <thead> <tr><th>Tarih<\/th><th>Fiyat Hareketi<\/th><th>Ana Kataliz\u00f6r<\/th><\/tr> <\/thead> <tbody> <tr><td>\u015eubat 2025<\/td><td>%74 art\u0131\u015f<\/td><td>Olumlu klinik deneme verisi beklentisi<\/td><\/tr> <tr><td>May\u0131s 2025<\/td><td>Sermaye art\u0131r\u0131m\u0131 tamamland\u0131<\/td><td>1,8 milyon \u20ac fon sa\u011fland\u0131<\/td><\/tr> <tr><td>Temmuz 2025<\/td><td>\u00d6zel yerle\u015ftirme tamamland\u0131<\/td><td>Ek 1,925 milyon \u20ac topland\u0131<\/td><\/tr> <tr><td>A\u011fustos 2025<\/td><td>Son sermaye art\u0131r\u0131m\u0131<\/td><td>2,55 milyon \u20ac fon enjeksiyonu<\/td><\/tr> <\/tbody> <\/table> <p>Hisse senedi, <strong>%31,63 y\u0131ll\u0131k kazan\u00e7<\/strong> g\u00f6stermi\u015f olmas\u0131na ra\u011fmen, son ayl\u0131k bask\u0131 <strong>-%7,06 d\u00fc\u015f\u00fc\u015f<\/strong> ya\u015fanm\u0131\u015f, bu da biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131n uzun vadeli iyimserlik ile k\u0131sa vadeli volatilite aras\u0131ndaki iki u\u00e7lu do\u011fas\u0131n\u0131 yans\u0131tmaktad\u0131r.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83c\udfaf Stratejik Giri\u015f Noktalar\u0131: Kazan\u00e7lar\u0131n Etki Analizi<\/h2> <p>Takviminize <strong>29 Eyl\u00fcl 2025<\/strong> tarihini i\u015faretleyin\u2014bu, AB Science'\u0131n yar\u0131y\u0131l sonu\u00e7lar\u0131n\u0131 a\u00e7\u0131klayaca\u011f\u0131 ve potansiyel b\u00fcy\u00fck volatilite tetikleyicisi olacak \u00f6nemli bir tarihtir. Tarihsel kazan\u00e7 tepkileri dikkat edilmesi gereken kal\u0131plar g\u00f6stermektedir:<\/p> <p>Temmuz 2025'teki klinik deneme onay haberleri, \u015eubat'taki %74'l\u00fck art\u0131\u015fa benzer olumlu bir momentum yaratm\u0131\u015ft\u0131r. \u015eirketin 2025 boyunca ger\u00e7ekle\u015ftirdi\u011fi ba\u015far\u0131l\u0131 sermaye art\u0131r\u0131mlar\u0131 (toplamda 6 milyon \u20ac'nun \u00fczerinde) sekt\u00f6r genelindeki finansman zorluklar\u0131na ra\u011fmen yat\u0131r\u0131mc\u0131 g\u00fcvenini s\u00fcrd\u00fcrd\u00fc\u011f\u00fcn\u00fc g\u00f6stermektedir.<\/p>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve klinik geli\u015fim seyri temelinde:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu Hedefi: 2,50-3,00\u20ac<\/strong> (%93-132 y\u00fckseli\u015f) <ul> <li>Masitinib Faz 3 deneme ilerlemesiyle destekleniyor<\/li> <li>Olas\u0131 olumlu ara veri a\u00e7\u0131klamalar\u0131<\/li> <li>Ba\u015far\u0131l\u0131 fon toplama devam\u0131<\/li> <\/ul> <\/li> <li><strong>2026 Projeksiyonu: 3,50-4,50\u20ac<\/strong> <ul> <li>FDA'n\u0131n \u00f6nc\u00fc tedavi tan\u0131m\u0131 alma ihtimali<\/li> <li>Ek kanser endikasyonlar\u0131na geni\u015fleme<\/li> <li>B\u00fcy\u00fck ila\u00e7 firmalar\u0131yla ortakl\u0131k f\u0131rsatlar\u0131<\/li> <\/ul> <\/li> <li><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc: 6,00-8,00\u20ac<\/strong> <ul> <li>Olas\u0131 ilk ticari onaylar<\/li> <li>Lisansl\u0131 b\u00f6lgelerden gelir elde edilmesi<\/li> <li>Masitinib d\u0131\u015f\u0131 \u00fcr\u00fcn hatt\u0131 geni\u015flemesi<\/li> <\/ul> <\/li> <li><strong>2030 Vizyonu: 10,00\u20ac+<\/strong> <ul> <li>Olu\u015fmu\u015f ticari varl\u0131k<\/li> <li>Birden fazla onaylanm\u0131\u015f endikasyon<\/li> <li>S\u00fcrd\u00fcr\u00fclebilir gelir b\u00fcy\u00fcmesi<\/li> <\/ul> <\/li> <\/ul> <p><strong>Mevcut Karar: G\u00dc\u00c7L\u00dc AL<\/strong> risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in<br> Ortalama analist fiyat hedefi 3,53\u20ac olup %173 potansiyel y\u00fckseli\u015f anlam\u0131na gelmekte, mevcut seviyeler uzun vadeli pozisyonlama i\u00e7in cazip k\u0131lmaktad\u0131r.<\/p>  <h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Biyoteknoloji Volatilitesinde Yol Alma<\/h2> <h3>Y\u00fcksek Risk Fakt\u00f6rleri<\/h3> <ul> <li><strong>Klinik Deneme Ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong>: Masitinib'in ba\u015far\u0131s\u0131 \u015firket de\u011ferlemesini belirler<\/li> <li><strong>Finansman K\u0131r\u0131lganl\u0131\u011f\u0131<\/strong>: Biyoteknoloji sekt\u00f6r\u00fcnde 2025'te %57 finansman d\u00fc\u015f\u00fc\u015f\u00fc<\/li> <li><strong>Reg\u00fclasyon Belirsizli\u011fi<\/strong>: FDA onay zamanlamalar\u0131 \u00f6ng\u00f6r\u00fclemez<\/li> <li><strong>\u0130kili Sonu\u00e7lar<\/strong>: Tek bir deneme sonucu g\u00fcnl\u00fck %20-30 hareketlere neden olabilir<\/li> <\/ul> <h3>2025 \u0130\u00e7in Olumlu Kataliz\u00f6rler<\/h3> <ul> <li><strong>\u00c7ift Reg\u00fclasyon Onay\u0131<\/strong>: FDA ve EMA, ALS ve prostat kanseri i\u00e7in Faz 3 denemelerini onaylad\u0131<\/li> <li><strong>Ba\u015far\u0131l\u0131 Fon Toplama<\/strong>: 2025'te 6+ milyon \u20ac toplanarak finansman s\u00fcresi uzat\u0131ld\u0131<\/li> <li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: Ya\u015flanan n\u00fcfus onkoloji talebini art\u0131r\u0131yor<\/li> <li><strong>Analist Deste\u011fi<\/strong>: 9 analist taraf\u0131ndan ortalama 3,53\u20ac hedef fiyat<\/li> <\/ul>  <h2>\ud83d\udcca Son B\u00fcy\u00fck Haberlerin Etki Analizi<\/h2> <p>Temmuz 2025, AB Science i\u00e7in iki b\u00fcy\u00fck reg\u00fclasyon zaferiyle d\u00f6n\u00fcm noktas\u0131 oldu:<\/p> <p><strong>4 Temmuz 2025<\/strong>: <a href=\"https:\/\/www.biospace.com\/press-releases\/ab-science-masitinib-receives-fda-and-ema-authorization-for-confirmatory-phase-3-trial-in-metastatic-castrate-resistant-prostate-cancer\">FDA ve EMA e\u015f zamanl\u0131 olarak<\/a> metastatik prostat kanseri i\u00e7in Faz 3 denemesini onaylad\u0131\u2014neredeyse yirmi y\u0131l sonra docetaxel ile ilk potansiyel hedefli kombinasyon.<\/p> <p><strong>24 Temmuz 2025<\/strong>: <a href=\"https:\/\/www.biospace.com\/press-releases\/ab-science-has-received-approval-from-several-european-countries-to-initiate-the-confirmatory-phase-3-study-of-masitinib-in-als\">Avrupa \u00fclkeleri<\/a> Faz 3 ALS \u00e7al\u0131\u015fmas\u0131n\u0131n ba\u015flat\u0131lmas\u0131n\u0131 onaylad\u0131 ve CTIS prosed\u00fcr\u00fcn\u00fcn her iki a\u015famas\u0131n\u0131 tamamlad\u0131.<\/p> <p>Bu onaylar, masitinib'in \u00e7oklu endikasyonlardaki mekanizmas\u0131n\u0131 do\u011frulayarak yat\u0131r\u0131m tezini \u00f6nemli \u00f6l\u00e7\u00fcde riskten ar\u0131nd\u0131rmakta ve \u00f6nemli yukar\u0131 potansiyelini korumaktad\u0131r.<\/p>  <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayanlar \u0130\u00e7in Bug\u00fcnk\u00fc \u0130\u015flem Plan\u0131<\/h2> <ol> <li><strong>Pozisyon B\u00fcy\u00fckl\u00fc\u011f\u00fc<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-5'inden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li> <li><strong>Ortalama Maliyetle Al\u0131m<\/strong>: Eyl\u00fcl kazan\u00e7lar\u0131ndan \u00f6nce hisseleri kademeli olarak biriktirin<\/li> <li><strong>Zarar Durdur Korumas\u0131<\/strong>: Volatilite riskini y\u00f6netmek i\u00e7in %15-20 zarar durdur seviyesi belirleyin<\/li> <li><strong>Kataliz\u00f6r Takvimi<\/strong>: 30 Eyl\u00fcl kazan\u00e7 ve klinik deneme kilometre ta\u015flar\u0131n\u0131 i\u015faretleyin<\/li> <\/ol> <p><em>Esprili deneyimli g\u00f6r\u00fc\u015f: \"AB Science ticareti yapmak, klinik denemeleri izlemek gibidir\u2014%90 sonu\u00e7lar\u0131 beklerken s\u0131k\u0131nt\u0131, %10 sonu\u00e7lar geldi\u011finde tam bir korku. Yan\u0131n\u0131za ekstra kahve ve mide koruyucu al\u0131n!\"<\/em><\/p>  <h2>\u2705 AB Science S.A. (AB) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Al\u0131m sat\u0131m platformu se\u00e7in<\/td><td>AB.PA listelemesi i\u00e7in Euronext Paris eri\u015fimini sa\u011flay\u0131n<\/td><\/tr> <tr><td>2<\/td><td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Y\u00fcksek volatilite nedeniyle k\u00fc\u00e7\u00fck pozisyonla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"AB.PA\" sembol\u00fcn\u00fc aray\u0131n<\/td><td>Do\u011fru borsa \u00f6zg\u00fc tan\u0131mlay\u0131c\u0131y\u0131 kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Limit emir t\u00fcr\u00fc se\u00e7in<\/td><td>Kaymay\u0131 \u00f6nlemek i\u00e7in maksimum giri\u015f fiyat\u0131 belirleyin<\/td><\/tr> <tr><td>5<\/td><td>Al\u0131m\u0131 ger\u00e7ekle\u015ftirin<\/td><td>D\u00fc\u015f\u00fck komisyon oranlar\u0131n\u0131 (&lt;%0,5) onaylay\u0131n<\/td><\/tr> <tr><td>6<\/td><td>Fiyat uyar\u0131lar\u0131 kurun<\/td><td>Kazan\u00e7 volatilitesi f\u0131rsatlar\u0131n\u0131 takip edin<\/td><\/tr> <tr><td>7<\/td><td>Yat\u0131r\u0131m tezini belgeleyin<\/td><td>Ana klinik kataliz\u00f6rleri ve zamanlamalar\u0131 not edin<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Pocket Option Biyoteknoloji Yat\u0131r\u0131mlar\u0131nda Neden \u00d6ne \u00c7\u0131k\u0131yor<\/h2> <p>Pocket Option, AB Science gibi volatil biyoteknoloji hisselerinde gezinmek i\u00e7in benzersiz avantajlar sunar:<\/p> <ul> <li><strong>Minimum 5$ depozito<\/strong>, yat\u0131r\u0131m tezlerini minimal riskle test etmeye olanak tan\u0131r\u2014g\u00fcnl\u00fck %20 hareketlerin yayg\u0131n oldu\u011fu ikili sonu\u00e7lu hisselerde kritik \u00f6nemdedir.<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama s\u00fcreci<\/strong>, klinik deneme sonu\u00e7lar\u0131 veya reg\u00fclasyon kararlar\u0131 an\u0131nda piyasaya yans\u0131rken f\u0131rsatlar\u0131 yakalaman\u0131z\u0131 sa\u011flar.<\/li> <li><strong>\u00c7e\u015fitli para \u00e7ekme se\u00e7enekleri<\/strong>, olumlu klinik veri a\u00e7\u0131klamalar\u0131n\u0131 takiben volatilite art\u0131\u015flar\u0131nda karlar\u0131 h\u0131zl\u0131ca g\u00fcvence alt\u0131na alman\u0131z\u0131 sa\u011flar.<\/li> <\/ul>  <h2>\ud83c\udf0d AB Science 2025'te: Klinik Yenilik Lideri<\/h2> <p>AB Science, kinaz inhibit\u00f6r\u00fc platformuyla ki\u015fiselle\u015ftirilmi\u015f t\u0131bb\u0131n \u00f6n saflar\u0131nda yer almaktad\u0131r. \u015eirketin biyobelirte\u00e7 odakl\u0131 hasta se\u00e7imine stratejik kay\u0131\u015f\u0131, hedefe y\u00f6nelik kanser tedavisinin gelece\u011fini temsil etmektedir. Mevcut piyasa konumu, klinik a\u015famadaki tipik bir biyoteknoloji \u015firketi olarak nakit yakarken umut vadeden bile\u015fenleri ileri a\u015fama denemelere ta\u015f\u0131maktad\u0131r.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: AB Science, biyoteknolojide nadir g\u00f6r\u00fclen bir ba\u015far\u0131ya imza atarak Temmuz 2025'te FDA ve EMA'dan e\u015f zamanl\u0131 Faz 3 deneme onay\u0131 alm\u0131\u015ft\u0131r; bu, g\u00fc\u00e7l\u00fc klinik verileri ve reg\u00fclasyon stratejisinin her iki b\u00fcy\u00fck ila\u00e7 pazar\u0131nda da ge\u00e7erlili\u011finin kan\u0131t\u0131d\u0131r.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 AB Science Hissesi: Mevcut Fiyat ve Piyasa Konumu<\/h2>\n<p>24 A\u011fustos 2025 itibar\u0131yla, AB Science S.A. (AB.PA) Euronext Paris&#8217;te <strong>1,29\u20ac<\/strong> fiyatla i\u015flem g\u00f6rmektedir. \u015eirketin piyasa de\u011feri yakla\u015f\u0131k 79,24 milyon euro olup, mikro-cap kategorisinde yer almakta\u2014y\u00fcksek b\u00fcy\u00fcme f\u0131rsatlar\u0131 ve buna ba\u011fl\u0131 risk seviyeleri arayan yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p>\n<p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131: 30 Eyl\u00fcl 2025<\/strong>, \u015firketin bir sonraki kazan\u00e7 a\u00e7\u0131klamas\u0131n\u0131 i\u015faret etmektedir. Tarihsel veriler, bu t\u00fcr olaylar\u0131n genellikle \u00f6nemli fiyat hareketlerine yol a\u00e7t\u0131\u011f\u0131n\u0131 g\u00f6stermektedir. \u00d6nceki kazan\u00e7 raporu 9 May\u0131s 2025&#8217;te yay\u0131mlanm\u0131\u015f olup, olumlu klinik deneme haberlerinin \u00f6nemli kazan\u00e7lar\u0131 tetikledi\u011fi g\u00f6r\u00fclm\u00fc\u015ft\u00fcr.<\/p>\n<h3>Son Fiyat Performans\u0131 Analizi<\/h3>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Fiyat Hareketi<\/th>\n<th>Ana Kataliz\u00f6r<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u015eubat 2025<\/td>\n<td>%74 art\u0131\u015f<\/td>\n<td>Olumlu klinik deneme verisi beklentisi<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>Sermaye art\u0131r\u0131m\u0131 tamamland\u0131<\/td>\n<td>1,8 milyon \u20ac fon sa\u011fland\u0131<\/td>\n<\/tr>\n<tr>\n<td>Temmuz 2025<\/td>\n<td>\u00d6zel yerle\u015ftirme tamamland\u0131<\/td>\n<td>Ek 1,925 milyon \u20ac topland\u0131<\/td>\n<\/tr>\n<tr>\n<td>A\u011fustos 2025<\/td>\n<td>Son sermaye art\u0131r\u0131m\u0131<\/td>\n<td>2,55 milyon \u20ac fon enjeksiyonu<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Hisse senedi, <strong>%31,63 y\u0131ll\u0131k kazan\u00e7<\/strong> g\u00f6stermi\u015f olmas\u0131na ra\u011fmen, son ayl\u0131k bask\u0131 <strong>-%7,06 d\u00fc\u015f\u00fc\u015f<\/strong> ya\u015fanm\u0131\u015f, bu da biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131n uzun vadeli iyimserlik ile k\u0131sa vadeli volatilite aras\u0131ndaki iki u\u00e7lu do\u011fas\u0131n\u0131 yans\u0131tmaktad\u0131r.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83c\udfaf Stratejik Giri\u015f Noktalar\u0131: Kazan\u00e7lar\u0131n Etki Analizi<\/h2>\n<p>Takviminize <strong>29 Eyl\u00fcl 2025<\/strong> tarihini i\u015faretleyin\u2014bu, AB Science&#8217;\u0131n yar\u0131y\u0131l sonu\u00e7lar\u0131n\u0131 a\u00e7\u0131klayaca\u011f\u0131 ve potansiyel b\u00fcy\u00fck volatilite tetikleyicisi olacak \u00f6nemli bir tarihtir. Tarihsel kazan\u00e7 tepkileri dikkat edilmesi gereken kal\u0131plar g\u00f6stermektedir:<\/p>\n<p>Temmuz 2025&#8217;teki klinik deneme onay haberleri, \u015eubat&#8217;taki %74&#8217;l\u00fck art\u0131\u015fa benzer olumlu bir momentum yaratm\u0131\u015ft\u0131r. \u015eirketin 2025 boyunca ger\u00e7ekle\u015ftirdi\u011fi ba\u015far\u0131l\u0131 sermaye art\u0131r\u0131mlar\u0131 (toplamda 6 milyon \u20ac&#8217;nun \u00fczerinde) sekt\u00f6r genelindeki finansman zorluklar\u0131na ra\u011fmen yat\u0131r\u0131mc\u0131 g\u00fcvenini s\u00fcrd\u00fcrd\u00fc\u011f\u00fcn\u00fc g\u00f6stermektedir.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve klinik geli\u015fim seyri temelinde:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu Hedefi: 2,50-3,00\u20ac<\/strong> (%93-132 y\u00fckseli\u015f)\n<ul>\n<li>Masitinib Faz 3 deneme ilerlemesiyle destekleniyor<\/li>\n<li>Olas\u0131 olumlu ara veri a\u00e7\u0131klamalar\u0131<\/li>\n<li>Ba\u015far\u0131l\u0131 fon toplama devam\u0131<\/li>\n<\/ul>\n<\/li>\n<li><strong>2026 Projeksiyonu: 3,50-4,50\u20ac<\/strong>\n<ul>\n<li>FDA&#8217;n\u0131n \u00f6nc\u00fc tedavi tan\u0131m\u0131 alma ihtimali<\/li>\n<li>Ek kanser endikasyonlar\u0131na geni\u015fleme<\/li>\n<li>B\u00fcy\u00fck ila\u00e7 firmalar\u0131yla ortakl\u0131k f\u0131rsatlar\u0131<\/li>\n<\/ul>\n<\/li>\n<li><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc: 6,00-8,00\u20ac<\/strong>\n<ul>\n<li>Olas\u0131 ilk ticari onaylar<\/li>\n<li>Lisansl\u0131 b\u00f6lgelerden gelir elde edilmesi<\/li>\n<li>Masitinib d\u0131\u015f\u0131 \u00fcr\u00fcn hatt\u0131 geni\u015flemesi<\/li>\n<\/ul>\n<\/li>\n<li><strong>2030 Vizyonu: 10,00\u20ac+<\/strong>\n<ul>\n<li>Olu\u015fmu\u015f ticari varl\u0131k<\/li>\n<li>Birden fazla onaylanm\u0131\u015f endikasyon<\/li>\n<li>S\u00fcrd\u00fcr\u00fclebilir gelir b\u00fcy\u00fcmesi<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><strong>Mevcut Karar: G\u00dc\u00c7L\u00dc AL<\/strong> risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in<br \/> Ortalama analist fiyat hedefi 3,53\u20ac olup %173 potansiyel y\u00fckseli\u015f anlam\u0131na gelmekte, mevcut seviyeler uzun vadeli pozisyonlama i\u00e7in cazip k\u0131lmaktad\u0131r.<\/p>\n<h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Biyoteknoloji Volatilitesinde Yol Alma<\/h2>\n<h3>Y\u00fcksek Risk Fakt\u00f6rleri<\/h3>\n<ul>\n<li><strong>Klinik Deneme Ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong>: Masitinib&#8217;in ba\u015far\u0131s\u0131 \u015firket de\u011ferlemesini belirler<\/li>\n<li><strong>Finansman K\u0131r\u0131lganl\u0131\u011f\u0131<\/strong>: Biyoteknoloji sekt\u00f6r\u00fcnde 2025&#8217;te %57 finansman d\u00fc\u015f\u00fc\u015f\u00fc<\/li>\n<li><strong>Reg\u00fclasyon Belirsizli\u011fi<\/strong>: FDA onay zamanlamalar\u0131 \u00f6ng\u00f6r\u00fclemez<\/li>\n<li><strong>\u0130kili Sonu\u00e7lar<\/strong>: Tek bir deneme sonucu g\u00fcnl\u00fck %20-30 hareketlere neden olabilir<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Olumlu Kataliz\u00f6rler<\/h3>\n<ul>\n<li><strong>\u00c7ift Reg\u00fclasyon Onay\u0131<\/strong>: FDA ve EMA, ALS ve prostat kanseri i\u00e7in Faz 3 denemelerini onaylad\u0131<\/li>\n<li><strong>Ba\u015far\u0131l\u0131 Fon Toplama<\/strong>: 2025&#8217;te 6+ milyon \u20ac toplanarak finansman s\u00fcresi uzat\u0131ld\u0131<\/li>\n<li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: Ya\u015flanan n\u00fcfus onkoloji talebini art\u0131r\u0131yor<\/li>\n<li><strong>Analist Deste\u011fi<\/strong>: 9 analist taraf\u0131ndan ortalama 3,53\u20ac hedef fiyat<\/li>\n<\/ul>\n<h2>\ud83d\udcca Son B\u00fcy\u00fck Haberlerin Etki Analizi<\/h2>\n<p>Temmuz 2025, AB Science i\u00e7in iki b\u00fcy\u00fck reg\u00fclasyon zaferiyle d\u00f6n\u00fcm noktas\u0131 oldu:<\/p>\n<p><strong>4 Temmuz 2025<\/strong>: <a href=\"https:\/\/www.biospace.com\/press-releases\/ab-science-masitinib-receives-fda-and-ema-authorization-for-confirmatory-phase-3-trial-in-metastatic-castrate-resistant-prostate-cancer\">FDA ve EMA e\u015f zamanl\u0131 olarak<\/a> metastatik prostat kanseri i\u00e7in Faz 3 denemesini onaylad\u0131\u2014neredeyse yirmi y\u0131l sonra docetaxel ile ilk potansiyel hedefli kombinasyon.<\/p>\n<p><strong>24 Temmuz 2025<\/strong>: <a href=\"https:\/\/www.biospace.com\/press-releases\/ab-science-has-received-approval-from-several-european-countries-to-initiate-the-confirmatory-phase-3-study-of-masitinib-in-als\">Avrupa \u00fclkeleri<\/a> Faz 3 ALS \u00e7al\u0131\u015fmas\u0131n\u0131n ba\u015flat\u0131lmas\u0131n\u0131 onaylad\u0131 ve CTIS prosed\u00fcr\u00fcn\u00fcn her iki a\u015famas\u0131n\u0131 tamamlad\u0131.<\/p>\n<p>Bu onaylar, masitinib&#8217;in \u00e7oklu endikasyonlardaki mekanizmas\u0131n\u0131 do\u011frulayarak yat\u0131r\u0131m tezini \u00f6nemli \u00f6l\u00e7\u00fcde riskten ar\u0131nd\u0131rmakta ve \u00f6nemli yukar\u0131 potansiyelini korumaktad\u0131r.<\/p>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayanlar \u0130\u00e7in Bug\u00fcnk\u00fc \u0130\u015flem Plan\u0131<\/h2>\n<ol>\n<li><strong>Pozisyon B\u00fcy\u00fckl\u00fc\u011f\u00fc<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-5&#8217;inden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li>\n<li><strong>Ortalama Maliyetle Al\u0131m<\/strong>: Eyl\u00fcl kazan\u00e7lar\u0131ndan \u00f6nce hisseleri kademeli olarak biriktirin<\/li>\n<li><strong>Zarar Durdur Korumas\u0131<\/strong>: Volatilite riskini y\u00f6netmek i\u00e7in %15-20 zarar durdur seviyesi belirleyin<\/li>\n<li><strong>Kataliz\u00f6r Takvimi<\/strong>: 30 Eyl\u00fcl kazan\u00e7 ve klinik deneme kilometre ta\u015flar\u0131n\u0131 i\u015faretleyin<\/li>\n<\/ol>\n<p><em>Esprili deneyimli g\u00f6r\u00fc\u015f: &#8220;AB Science ticareti yapmak, klinik denemeleri izlemek gibidir\u2014%90 sonu\u00e7lar\u0131 beklerken s\u0131k\u0131nt\u0131, %10 sonu\u00e7lar geldi\u011finde tam bir korku. Yan\u0131n\u0131za ekstra kahve ve mide koruyucu al\u0131n!&#8221;<\/em><\/p>\n<h2>\u2705 AB Science S.A. (AB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Al\u0131m sat\u0131m platformu se\u00e7in<\/td>\n<td>AB.PA listelemesi i\u00e7in Euronext Paris eri\u015fimini sa\u011flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Y\u00fcksek volatilite nedeniyle k\u00fc\u00e7\u00fck pozisyonla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;AB.PA&#8221; sembol\u00fcn\u00fc aray\u0131n<\/td>\n<td>Do\u011fru borsa \u00f6zg\u00fc tan\u0131mlay\u0131c\u0131y\u0131 kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Limit emir t\u00fcr\u00fc se\u00e7in<\/td>\n<td>Kaymay\u0131 \u00f6nlemek i\u00e7in maksimum giri\u015f fiyat\u0131 belirleyin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Al\u0131m\u0131 ger\u00e7ekle\u015ftirin<\/td>\n<td>D\u00fc\u015f\u00fck komisyon oranlar\u0131n\u0131 (&lt;%0,5) onaylay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Fiyat uyar\u0131lar\u0131 kurun<\/td>\n<td>Kazan\u00e7 volatilitesi f\u0131rsatlar\u0131n\u0131 takip edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Yat\u0131r\u0131m tezini belgeleyin<\/td>\n<td>Ana klinik kataliz\u00f6rleri ve zamanlamalar\u0131 not edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Biyoteknoloji Yat\u0131r\u0131mlar\u0131nda Neden \u00d6ne \u00c7\u0131k\u0131yor<\/h2>\n<p>Pocket Option, AB Science gibi volatil biyoteknoloji hisselerinde gezinmek i\u00e7in benzersiz avantajlar sunar:<\/p>\n<ul>\n<li><strong>Minimum 5$ depozito<\/strong>, yat\u0131r\u0131m tezlerini minimal riskle test etmeye olanak tan\u0131r\u2014g\u00fcnl\u00fck %20 hareketlerin yayg\u0131n oldu\u011fu ikili sonu\u00e7lu hisselerde kritik \u00f6nemdedir.<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama s\u00fcreci<\/strong>, klinik deneme sonu\u00e7lar\u0131 veya reg\u00fclasyon kararlar\u0131 an\u0131nda piyasaya yans\u0131rken f\u0131rsatlar\u0131 yakalaman\u0131z\u0131 sa\u011flar.<\/li>\n<li><strong>\u00c7e\u015fitli para \u00e7ekme se\u00e7enekleri<\/strong>, olumlu klinik veri a\u00e7\u0131klamalar\u0131n\u0131 takiben volatilite art\u0131\u015flar\u0131nda karlar\u0131 h\u0131zl\u0131ca g\u00fcvence alt\u0131na alman\u0131z\u0131 sa\u011flar.<\/li>\n<\/ul>\n<h2>\ud83c\udf0d AB Science 2025&#8217;te: Klinik Yenilik Lideri<\/h2>\n<p>AB Science, kinaz inhibit\u00f6r\u00fc platformuyla ki\u015fiselle\u015ftirilmi\u015f t\u0131bb\u0131n \u00f6n saflar\u0131nda yer almaktad\u0131r. \u015eirketin biyobelirte\u00e7 odakl\u0131 hasta se\u00e7imine stratejik kay\u0131\u015f\u0131, hedefe y\u00f6nelik kanser tedavisinin gelece\u011fini temsil etmektedir. Mevcut piyasa konumu, klinik a\u015famadaki tipik bir biyoteknoloji \u015firketi olarak nakit yakarken umut vadeden bile\u015fenleri ileri a\u015fama denemelere ta\u015f\u0131maktad\u0131r.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: AB Science, biyoteknolojide nadir g\u00f6r\u00fclen bir ba\u015far\u0131ya imza atarak Temmuz 2025&#8217;te FDA ve EMA&#8217;dan e\u015f zamanl\u0131 Faz 3 deneme onay\u0131 alm\u0131\u015ft\u0131r; bu, g\u00fc\u00e7l\u00fc klinik verileri ve reg\u00fclasyon stratejisinin her iki b\u00fcy\u00fck ila\u00e7 pazar\u0131nda da ge\u00e7erlili\u011finin kan\u0131t\u0131d\u0131r.<\/p>\n"},"faq":[{"question":"AB Science hisseleri nereden al\u0131nabilir?","answer":"AB Science hisseleri, Euronext Paris borsas\u0131nda \"AB.PA\" sembol\u00fc ile i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online yat\u0131r\u0131m platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"AB Science hisseleri i\u00e7in riskler nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131 volatilite, finansman zorluklar\u0131, reg\u00fclasyon belirsizlikleri ve tek bir deneme sonucunun hisse fiyat\u0131nda b\u00fcy\u00fck dalgalanmalara yol a\u00e7abilmesi bulunmaktad\u0131r."},{"question":"AB Science hisseleri i\u00e7in 2025-2030 fiyat tahmini nedir?","answer":"Analistlerin ortalama tahminlerine g\u00f6re, 2025 sonunda fiyat 2,50-3,00\u20ac aral\u0131\u011f\u0131nda, 2030 y\u0131l\u0131nda ise 10,00\u20ac ve \u00fczeri seviyelerde olabilir."},{"question":"Yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesini ay\u0131rmak, zarar durdur emirleri kullanmak, kademeli al\u0131m yapmak ve \u00f6nemli kazan\u00e7 a\u00e7\u0131klama tarihlerini takip etmek \u00f6nemlidir."},{"question":"Pocket Option biyoteknoloji yat\u0131r\u0131mlar\u0131 i\u00e7in neden tercih edilmeli?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama s\u00fcreci ve \u00e7e\u015fitli para \u00e7ekme se\u00e7enekleri ile volatil biyoteknoloji hisselerinde h\u0131zl\u0131 ve esnek i\u015flem yapma imkan\u0131 sunar."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"AB Science hisseleri nereden al\u0131nabilir?","answer":"AB Science hisseleri, Euronext Paris borsas\u0131nda \"AB.PA\" sembol\u00fc ile i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online yat\u0131r\u0131m platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"AB Science hisseleri i\u00e7in riskler nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131 volatilite, finansman zorluklar\u0131, reg\u00fclasyon belirsizlikleri ve tek bir deneme sonucunun hisse fiyat\u0131nda b\u00fcy\u00fck dalgalanmalara yol a\u00e7abilmesi bulunmaktad\u0131r."},{"question":"AB Science hisseleri i\u00e7in 2025-2030 fiyat tahmini nedir?","answer":"Analistlerin ortalama tahminlerine g\u00f6re, 2025 sonunda fiyat 2,50-3,00\u20ac aral\u0131\u011f\u0131nda, 2030 y\u0131l\u0131nda ise 10,00\u20ac ve \u00fczeri seviyelerde olabilir."},{"question":"Yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesini ay\u0131rmak, zarar durdur emirleri kullanmak, kademeli al\u0131m yapmak ve \u00f6nemli kazan\u00e7 a\u00e7\u0131klama tarihlerini takip etmek \u00f6nemlidir."},{"question":"Pocket Option biyoteknoloji yat\u0131r\u0131mlar\u0131 i\u00e7in neden tercih edilmeli?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama s\u00fcreci ve \u00e7e\u015fitli para \u00e7ekme se\u00e7enekleri ile volatil biyoteknoloji hisselerinde h\u0131zl\u0131 ve esnek i\u015flem yapma imkan\u0131 sunar."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AB Science S.A. (AB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AB Science S.A. (AB) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AB Science S.A. (AB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AB Science S.A. (AB) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-24T14:26:21+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"AB Science S.A. (AB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AB Science S.A. (AB) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-24T14:26:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/\"},\"wordCount\":23,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/\",\"name\":\"AB Science S.A. (AB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AB Science S.A. (AB) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"datePublished\":\"2025-08-24T14:26:21+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AB Science S.A. (AB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AB Science S.A. (AB) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AB Science S.A. (AB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AB Science S.A. (AB) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/","og_locale":"tr_TR","og_type":"article","og_title":"AB Science S.A. (AB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AB Science S.A. (AB) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-24T14:26:21+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"AB Science S.A. (AB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AB Science S.A. (AB) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-24T14:26:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/"},"wordCount":23,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/","name":"AB Science S.A. (AB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AB Science S.A. (AB) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","datePublished":"2025-08-24T14:26:21+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"AB Science S.A. (AB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AB Science S.A. (AB) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":344941,"slug":"how-to-buy-ab-science-sa","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu AB Science S.A. (AB) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu AB Science S.A. (AB)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-ab-science-sa\/"},"pt_AA":{"locale":"pt_AA","id":344940,"slug":"how-to-buy-ab-science-sa","post_title":"Como comprar a\u00e7\u00f5es da AB Science S.A. (AB) - Investimento em a\u00e7\u00f5es da AB Science S.A. (AB)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-ab-science-sa\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/344948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=344948"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/344948\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334099"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=344948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=344948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=344948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}